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Abstract
Oligodendrocytes associate with axons to establish myelin and provide metabolic support to 
neurons. In the spinal cord of ALS mice, oligodendrocytes downregulate transporters that transfer 
glycolytic substrates to neurons and oligodendrocyte progenitors (NG2+ cells) exhibit enhanced 
proliferation and differentiation, although the cause of these changes in oligodendroglia is 
unknown. Here we report that there is extensive degeneration of gray matter oligodendrocytes in 
the spinal cord of ALS mice before disease onset. Although new oligodendrocytes were formed, 
they failed to mature, resulting in progressive demyelination. Oligodendrocyte dysfunction also is 
prevalent in human ALS, as gray matter demyelination and reactive changes in NG2+ cells were 
observed in motor cortex and spinal cord of ALS patients. Selective removal of mutant SOD1 
from oligodendroglia substantially delayed disease onset and prolonged survival in ALS mice, 
suggesting that ALS-linked genes enhance the vulnerability of motor neurons and accelerate 
disease by directly impairing the function of oligodendrocytes.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease 
characterized by progressive muscle weakness and eventual paralysis. Although disease 
culminates in the degeneration of motor neurons, non-neuronal cells such as astrocytes and 
microglia have been shown to play critical roles in the pathogenic process of ALS1–4. ALS-
linked genes such as Sod1 are expressed in glia as well as motor neurons, and glial cell 
dysfunction appears to exacerbate injury to motor neurons, as selective removal of mutant 
SOD1 from subsets of glia slows disease progression2, 3. However, the vulnerability of 
distinct populations of glial cells to disease-induced stress, and the contribution of these 
alterations to the pathogenesis of ALS are not well understood.
Degeneration of motor neurons in the spinal cord is associated with reactive changes in 
surrounding glia that include cellular hypertrophy and enhanced proliferation. In particular, 
recent studies indicate that the behavior of NG2+ glial cells, a distinct, widely distributed 
class of progenitor cells that have the capacity to differentiate into oligodendrocytes, is 
dramatically altered in the spinal cord of ALS (SOD1 (G93A)) mice5, 6. By end stage of 
disease, NG2+ cells exhibit the highest rate of proliferation of any cell type in the spinal 
cord, and their differentiation into oligodendrocytes is markedly enhanced5, suggesting that 
there may be a progressive dysfunction of oligodendrocytes in ALS.
In addition to their key role in forming myelin, there is emerging evidence that 
oligodendrocytes provide crucial metabolic support to neurons7, 8. The monocarboxylic acid 
transporter 1 (MCT1), a transporter that motor neurons depend on for transfer of glycolytic 
substrates9, 10 is expressed predominantly by oligodendrocytes9, 11 and downregulated in the 
motor cortex of ALS patients and the spinal cord of the SOD1 (G93A) mouse model of 
ALS9. Together, these profound abnormalities in the oligodendrocyte lineage in ALS may 
impact motor neuron survival; however, the cause of the enhanced proliferation and 
differentiation of oligodendrocyte progenitors in ALS mice, and the extent of 
oligodendrocyte abnormalities in human ALS12, 13 are uncertain.
Using in vivo genetic fate tracing of oligodendrocytes and their progenitors, we discovered 
that there was extensive, progressive degeneration of oligodendrocytes in the spinal cord of 
ALS mice, with less than half of the oligodendrocytes produced in first postnatal month 
surviving by end stage of disease. Mobilization of oligodendrocyte progenitors occurred first 
in the ventral gray matter, where motor neurons are located, prior to behavioral 
manifestation of disease; however, newly formed oligodendrocytes in this region exhibited 
abnormal morphologies and failed to fully differentiate. Dysfunction of gray matter 
oligodendrocytes also was prevalent in human ALS, as reactive changes in NG2+ cells and 
demyelination were observed in gray matter of the ventral spinal cord and motor cortex of 
ALS patients. Genetic deletion of mutant human SOD1 (G37R) from NG2+ cells and their 
oligodendrocyte progeny in mice substantially delayed disease onset and prolonged survival, 
indicating that expression of this ALS-linked gene in the oligodendrocyte lineage accelerates 
motor neuron degeneration. The progressive loss of gray matter oligodendrocytes, and 
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failure to restore these crucial cells, may accelerate disease progression in ALS by depriving 
motor neurons of essential metabolic support.
RESULTS
Enhanced proliferation of NG2+ cells in young ALS mice
The progressive loss of motor neurons in SOD1 (G93A) ALS mice is accompanied by 
prominent changes in the behavior of NG2+ cells5. By end stage of disease, their 
proliferation rate is 20-fold higher than in wild type mice5, and they comprise the majority 
of actively dividing cells in the spinal cord5, 6. However, the cause of the enhanced 
proliferation of these glial cells in ALS is unknown. To define when and where NG2+ cells 
first exhibit this altered behavior, we examined the spatio-temporal profile of NG2+ cell 
proliferation over the course of disease. Mice were administered BrdU for five days and 
cumulative BrdU incorporation was measured in lumbar spinal cord (Fig. 1a,b and 
Supplementary Fig. 1a). In wild type mice, the number of BrdU+ NG2+ cells declined with 
age in all regions examined (P < 0.001, one-way ANOVA) (Fig. 1c–e), following the 
developmental decline in generation of oligodendrocytes from these progenitors5, 14, 15. 
However, in SOD1 (G93A) mice, NG2+ cells sustained high rates of proliferation into 
adulthood (Fig. 1c–e). Moreover, unlike the uniform decline in proliferation in wild type 
mice, NG2+ cells in SOD1 (G93A) mice exhibited regional differences in their response. 
Enhanced proliferation was most prominent in ventral gray matter, where their rate of 
division was elevated 2.3-fold compared to control mice by P60 (P < 0.001, Student’s t-
test), before ALS mice show disease symptoms16, and 12.9-fold by P95 (P < 0.0005), after 
they exhibit muscle weakness and tremor17. NG2+ cells in ventral white and dorsal gray 
matter of ALS mice eventually exhibited enhanced proliferation, although it occurred later 
and the magnitude of increased cell division was lower than in ventral gray matter (Fig. 1c–
e). Thus, NG2+ cells in SOD1 (G93A) mice display abnormal behavior in ventral gray 
matter before behavioral manifestation of disease.
Despite the enhanced generation of NG2+ cells in early stages of disease, their density was 
not significantly altered until end stage (Fig. 1f–h), suggesting that they are continually 
removed through death or differentiation. To determine the fate of NG2+ cells at early stages 
of disease, genetic lineage tracing was performed using PDGFαR-CreER;Z/EG mice5. After 
breeding to SOD1 (G93A) mice, cohorts of NG2+ cells were induced to express EGFP by 
administering 4-hydroxytamoxifen (4HT) at P30 or P60, and the identity of EGFP+ cells in 
lumbar spinal cord was determined 15 – 60 days later (Fig. 2a and Supplementary Fig. 1b,c). 
In accordance with the regional differences in NG2+ cell proliferation, more EGFP+ cells 
were observed in ventral gray matter by P90 in SOD1 (G93A) mice (Fig. 2b and 
Supplementary Fig. 1d–f), while the number of EGFP+ cells in other areas was not 
significantly increased relative to controls. However, by end stage, EGFP+ cell density in 
SOD1 (G93A) mice was higher than controls in all regions examined, with ventral gray 
matter exhibiting the greatest accumulation of NG2+ cell progeny (Supplementary Fig. 1d–
f). As the number of EGFP+ cells should remain constant if they have an equal probability of 
dividing or dying, these results suggest that the enhanced proliferation of NG2+ cells is not 
induced solely by accelerated death of these progenitors.
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Oligodendrogenesis without oligodendrocyte accumulation
NG2+ cells in the spinal cord of end stage SOD1 (G93A) mice not only proliferate more 
rapidly, but also differentiate more frequently into oligodendrocytes5. To determine where 
and when this increase in oligodendrogenesis occurs, in PDGFαR-CreER;Z/EG ± SOD1 
(G93A) mice we followed the appearance of EGFP+ cells that were immunoreactive to anti-
APC (CC1), a feature of mature oligodendrocytes. when and where this increase in 
oligodendrogenesis occurs, we followed the appearance of EGFP+ cells in PDGFαR-
CreER;Z/EG ± SOD1 (G93A) mice that were immunoreactive to anti-APC (CC1), a feature 
of mature oligodendrocytes. In accordance with the early maturation of myelinated tracts in 
the spinal cord18, few oligodendrocytes (EGFP+CC1+ cells) were generated from P60 P120 
in controls (Fig. 2c–h). In contrast, there was a marked increase in newly generated 
oligodendrocytes in ventral gray matter of ALS mice (P < 0.001, one-way ANOVA)(Fig. 
2c–f); there were 10.9-fold more EGFP+CC1+ cells in this region relative to controls 60 
days after labeling (P < 0.0005, Student’s t-test) (Fig. 2f).
An increase in EGFP+ oligodendrocytes also was observed in ventral white matter at P90 
and end stage in ALS mice, although this increase was smaller than in ventral gray matter 
(Fig. 2g), and there was no significant change in EGFP+ oligodendrocytes relative to control 
in dorsal gray matter (Fig. 2g,h). As the fate of only a small fraction (~ 15%) of NG2+ cells 
was followed in these experiments, the total number of oligodendrocytes generated during 
this period is expected to be much greater (by ~ 6–7-fold). Despite this profound increase in 
oligodendrogenesis, the overall density of oligodendrocytes in the spinal cord of SOD1 
(G93A) mice at end stage was unchanged relative to controls (Fig. 2i). These results suggest 
that there must be a concomitant loss of oligodendrocytes with advancing disease.
Degeneration of early-born oligodendrocytes in ALS mice
To determine the extent of oligodendrocyte survival during the course of disease, we 
performed genetic fate tracing of oligodendrocytes using PLP-CreER;ROSA26-EYFP ± 
SOD1 (G93A) mice (Fig. 3a,b). Administration of 4HT at P35 resulted in labeling of 15 – 25 
% of oligodendrocytes in ventral gray and white matter regions of the spinal cord. Although 
cre-mediated recombination occurs in some NG2+ cells in the brains of PLP-
CreER;ROSA26-EYFP mice19, EYFP was not expressed by these progenitors in the spinal 
cord of either control or SOD1 (G93A) mice (Supplementary Fig. 2), indicating that this 
approach can be used to track the survival of spinal cord oligodendrocytes in vivo. 
Quantitative analysis of spinal cords sampled at early time points revealed that the number 
of EYFP+ oligodendrocytes increased gradually for the first two weeks after 4HT 
administration in both control and SOD1 (G93A) mice19 and initial labeling of these cells 
was significantly higher in SOD1 (G93A) mice than controls in ventral gray matter (at 
P35+15), possibly reflecting enhanced activity of the PLP transgene promoter. To allow 
direct comparison of oligodendrocyte survival between control and ALS mice, the number 
of EYFP labeled oligodendrocytes in each cohort was normalized to that observed at 
P35+15, when oligodendrocyte labeling in SOD1 (G93A) mice was near maximum (Fig. 
3c,d). In control mice, there was a small increase in EYFP+ oligodendrocytes in lumbar 
spinal cord (EYFP+CC1+Olig2+) 40 and 70 days after initial labeling (at P50) (Fig. 3c), 
indicating a modest, but continuous labeling of oligodendrocytes during this period. In 
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contrast, the number of EYFP+ oligodendrocytes in SOD1 (G93A) mice was reduced by 22 
% 40 days after labeling (P < 0.05, one-way ANOVA with Tukey) (Fig. 3c). This loss was 
progressive, as the number of labeled oligodendrocytes was reduced by 65 % at end stage (P 
< 0.0005, one-way ANOVA) (Fig. 3c,e). Moreover, as expected from the regional difference 
in NG2+ cell proliferation and oligodendrogenesis, loss of early-born oligodendrocytes in 
ALS mice was most prominent in ventral gray matter (Fig. 3c,d). These results indicate that 
there is already pronounced degeneration of oligodendrocytes in ventral gray matter near 
motor neurons when mice first exhibit overt signs of disease.
If oligodendrocytes degenerate in the spinal cord of ALS mice, other indications of cell 
death should be visible. Indeed, some EGFP expressing oligodendrocytes were 
immunopositive for activated Caspase-3 in the spinal cord of end stage MOBP-EGFP;SOD1 
(G93A) mice (Fig. 4a), in which only mature oligodendrocytes express EGFP 
(Supplementary Fig. 3). Moreover, dense cell clusters consisting of EGFP+ oligodendrocytes 
surrounded by activated microglial cells were observed at P90 in ventral gray matter (Fig. 
4b). In accordance with the death of early born oligodendrocytes observed through genetic 
fate tracing, similar microglia-oligodendrocyte (EYFP+) aggregates were observed in P90 
PLP-CreER;ROSA26-EYFP;SOD1 (G93A) mice, in which oligodendrocytes were labeled at 
P35 (P35+55) (Fig. 4c); however, microglial clustering was not observed near GFAP+ 
astrocytes (Fig. 4c). As microglia are attracted to apoptotic cells20, the presence of these cell 
aggregates may indicate that mature oligodendrocytes in this region were dying through 
apoptotic death.
Widespread axonal degeneration can lead to loss of oligodendrocytes and reactive changes 
in their progenitors21, 22, raising the possibility that degeneration of gray matter 
oligodendrocytes in ALS mice is secondary to motor neuron degeneration. To address 
whether loss of motor neurons is sufficient to induce mobilization of NG2+ cells, we 
partially ablated motor neurons by injecting ricin into the sciatic nerve23. One week after 
this manipulation, approximately half of the motor neurons in the ventral horn had 
degenerated on the side ipsilateral to the injection (P < 0.0005, paired Student’s t-test) 
(Supplementary Fig. 4a–c). However, neither the morphology nor the proliferation rate of 
NG2+ cells, as assessed by NG2 and Ki67 immunoreactivity, respectively, was altered by 
this loss of motor neurons (Supplementary Fig. 4b,d) suggesting that acute motor neuron 
death is not sufficient to induce activation and recruitment of these progenitors.
To determine when oligodendrocytes begin to exhibit abnormalities in ALS mice, we 
examined their morphology in MOBP-EGFP ± SOD1 (G93A) mice at different stages of 
disease. Oligodendrocyte somata (EGFP+Olig2+) in the spinal cord of control MOBP-EGFP 
mice had a consistent oval shape (Fig. 5a upper panel and Supplementary Fig. 3). In the 
spinal cord of end stage MOBP-EGFP;SOD1 (G93A) mice, there was a dramatic increase in 
irregularly shaped EGFP+ structures, many of which were Olig2− and lacked nuclei (Fig. 5b 
lower panel and Supplementary Fig. 5a), reminiscent of the fragmentation that occurs during 
apoptotic cell death24. Despite this increase in EGFP+ structures, the density of 
EGFP+Olig2+ oligodendrocytes in end stage SOD1 (G93A) mice was not different from 
control (Control: 1137 ± 61 cells; SOD1 (G93A): 1233 ± 73 cells, n = 9 sections, 3 mice per 
group, P = 0.33, Student’s t-test), consistent with results obtained using CC1 
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immunoreactivity (see Fig. 2i). Irregularly shaped EGFP+ oligodendrocyte somata with 
reduced or absent Olig2 immunoreactivity also were observed at earlier stages of disease 
(Supplementary Fig. 5b,c). To evaluate the progressive nature of these changes, the area of 
EGFP+ cell fragments was measured following digital subtraction of EGFP+Olig2+ somata 
(Supplementary Fig. 5d). EGFP+ cellular fragments were evident at P90 in SOD1 (G93A) 
mice, but rarely observed in aged matched controls (volume of fragments: Control: 10 ± 5.1 
μm3; SOD1 (G93A): 131 ± 13 μm3, P < 1.0 × 10−5, Student’s t-test) (Fig. 5c), indicating that 
pathological alterations in oligodendrocytes are widespread by the time mice begin to show 
behavioral manifestation of disease.
Myelin deficits in spinal cord gray matter of ALS mice
The accelerated turnover (i.e. death and subsequent regeneration) and abnormal structure of 
oligodendrocytes in ALS mice, suggests that the state of myelination in gray matter may be 
altered in disease. Indeed, electron microscopic (EM) analysis of ventral gray matter 
revealed that the proportion of ultrastructurally normal axons with immature myelin, as 
evidenced by the presence of a thick layer of oligodendrocyte cytoplasm between the axon 
and initial myelin wraps, was 49 % higher in end stage SOD1 (G93A) mice compared to 
age-matched controls (percentage of axons with immature myelin: Control: 9.3 ± 1.2 %; 
SOD1 (G93A): 13.9 ± 1.0 %, n = 3 mice per group, P < 0.01, unpaired Student’s t-test) (Fig. 
6a), suggesting that viable, uninjured axons were being remyelinated in ALS mice. Axons 
with disorganized microtubules, electron dense bodies and spheroids surrounded by swollen, 
electron dense myelin, typical of Wallerian degeneration17 also were common in the ventral 
gray matter of SOD1 (G93A) mice (Supplementary Fig. 6a). Moreover, myelin basic protein 
(MBP) immunoreactivity was more diffuse in ventral gray matter of SOD1 (G93A) mice at 
end stage and often not co-localized with EGFP, in contrast to the filamentous EGFP+ 
processes present in control MOBP-EGFP mice (Fig. 6b). Axons with mature myelin had 
thicker myelin sheaths and lower g ratios in SOD1 (G93A) mice compared to controls 
(Supplementary Fig. 6b–d), possibly reflecting shrinkage of axons from metabolic stress or 
abnormal patterns of gene expression in oligodendrocytes.
To determine the structure of oligodendrocytes generated after P60, we used membrane 
anchored EGFP Cre reporter mice ROSA26-mEGFP (mT/mG) to visualize their fine cellular 
processes5. PDGFαR-CreER;ROSA26-mEGFP ± SOD1 (G93A) mice were injected with 
4HT at P60 and analyzed two months later (Fig. 6c). In control mice (P60+60), numerous 
thin, unbranched EGFP+ processes were visible throughout the ventral gray matter, 
consistent with the morphology of normal internodal segments (Fig. 6d upper panel). 
Although oligodendrocytes generated after P60 in SOD1 (G93A) mice also were CC1+ (see 
Fig. 2c–e), their processes were highly branched with numerous varicosities (Fig. 6d lower 
panel); the processes of these newly generated oligodendrocytes often did not co-localize 
with MBP, in contrast to oligodendrocyte processes in controls (Fig. 6e). Immunogold EM 
labeling of EGFP revealed that adult-born oligodendrocytes in SOD1 (G93A) mice were 
frequently associated with degenerating axons (Fig. 6f,g), suggesting that these axons had 
experienced at least one round of demyelination and remyelination. In addition, there were 
many irregularly shaped, immunogold-positive structures in SOD1 (G93A) mice that were 
not associated with axons (Fig. 6h), reminiscent of the oligodendrocyte fragmentation 
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observed through confocal microscopy (see Fig. 5b). Thus, oligodendrocytes generated in 
this disease context do not achieve the normal structure of myelinating oligodendrocytes.
Despite the presence of some axons with thicker myelin in SOD1 (G93A) mice, western blot 
analysis indicated that myelin-associated proteins MBP, CNPase (2′, 3′,- cyclic nueotide-3′-
phosphodiesterase), and MOG (myelin-oligodendrocyte glycoprotein) progressively 
decreased with age (Supplementary Fig. 7a,b), with the mature myelin protein MOG 
exhibiting the earliest decline by P60; this reduction in myelin was most prominent in 
ventral gray matter (Supplementary Fig. 7c). The decrease in myelin protein expression was 
accompanied by a concomitant increase in PDGFαR expression in both symptomatic (P90) 
and end stage mice (Supplementary Fig. 7a,b). Although NG2+ cell density in the spinal 
cord of SOD1 (G93A) mice was not significantly changed at earlier stages of disease (see 
Fig. 2f–h), the increased expression of PDGFαR from P90 is consistent with progressive 
mobilization of these progenitors in response to the loss of oligodendrocytes25–27. Together, 
these findings indicate that myelination is significantly disrupted in the spinal cord ventral 
gray matter of ALS mice.
Reactive NG2+ cells and focal demyelination in ALS
NG2+ cells are abundant in the human CNS and are likely to be major contributors to the 
regeneration of oligodendrocytes in demyelinating diseases such as multiple sclerosis 
(MS)28. To determine whether NG2+ cells also undergo reactive changes in ALS patients, 
immunohistochemistry was performed on human motor cortices. Motor cortex was analyzed 
rather than spinal cord, as this tissue is better preserved in human autopsies, which is 
required to preserve the NG2 proteoglycan. Sections also were immunostained for the 
microglial antigen Iba1 to distinguish NG2+ glial cells from NG2 expressing macrophages/
microglia that often appear in chronic disease and CNS injury29, 30. NG2 immunoreactivity 
was markedly higher in the motor cortex of ALS patients, compared to either motor cortex 
from non-ALS subjects (Control: 106.2 ± 5.3 %; ALS: 200.2 ± 9.4 %, P < 0.0001, unpaired 
Student’s t-test) or occipital cortex from the same patients, as determined by the intensity of 
NG2-immunoreactivity (Fig. 7a; Supplementary Fig. 8a,b). Although NG2+Iba1+cells were 
observed in both control and ALS motor cortex, thicker NG2+ processes that exhibited signs 
of hypertrophy in ALS tissue were Iba1− (Supplementary Fig. 8a), indicating that NG2+ 
glial cells exhibit reactive changes in regions of brain where motor neurons degenerate in 
ALS.
To assess whether these changes in NG2+ cells also were associated with degeneration of 
oligodendrocytes in gray matter, we examined the integrity of myelin in motor cortex and 
spinal cord of sporadic and familial ALS patients. Myelin staining (Luxol fast blue) and 
MBP immunolabeling revealed areas of focal loss of myelin in motor cortex gray matter of 
ALS patients that were not observed in control patients (Fig. 7b,c) (see Supplementary Table 
1). Moreover, in addition to the well-described reduction in myelination of corticospinal 
tracts, myelin was also reduced in ventral horn gray matter of the spinal cord from ALS 
patients (Fig. 7d). To quantify the extent of myelin loss, MBP and CNPase abundance was 
determined in randomly sampled regions of primary motor cortex gray matter (Fig. 7e,f and 
Supplementary Fig. 8c,d), as well as spinal cord ventral gray matter (Fig. 7g,h). MBP 
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expression was significantly lower in most ALS patients relative to controls, while CNPase 
levels were significantly reduced in one patient and trended lower in a second patient. 
Furthermore, the reduction in expression of myelin proteins was greater in motor cortices as 
compared to occipital cortices in the same ALS patients, consistent with motor cortex 
specific lesions (Supplementary Fig. 8c,d). Although it is not yet possible to determine the 
relative contributions of primary oligodendrocyte death and secondary oligodendrocyte 
death due to Wallerian degeneration in these tissues, these results indicate that 
demyelination of gray matter regions where motor neurons are located is a common feature 
of human ALS.
Mutant SOD1 deletion from oligodendroglia reduces disease
Oligodendrocytes are vulnerable to damage through cell-autonomous expression of genes 
linked to neurodegeneration31, 32, particularly aggregation-prone proteins, raising the 
possibility that expression of mutant SOD1 in oligodendrocytes may impair their function 
and promote motor neuron degeneration. To determine if there is an oligodendroglial 
contribution to disease in ALS, we selectively removed mutant human SOD1 (G37R) from 
NG2+ cells in PDGFαR-CreER;loxSOD1(G37R) mice2. Administration of 4HT to these 
animals at P18 and P30 to selectively removesignificantly decreased SOD1 (G37R) gene 
level in NG2+ cells by ~ 43 % as determined by qPCR (Fig. 8d), but preserved its expression 
in motor neurons (Supplementary Fig. 11a); this approach had little impact on overall tissue 
levels of SOD1 (G37R) (Supplementary Fig. 11b,c), in keeping with the relatively small 
number of NG2+ cells present (2–5 % of all neural cells in the spinal cord)33. However, 
selective removal of SOD1 (G37R) from oligodendroglia profoundly delayed disease onset 
by 69 days (median, P = 0.0002), delayed early disease by 83 days (median, P = 0.0002), 
and prolonged survival by more than 130 days (median, P < 0.005) (Fig. 8a,b). Consistent 
with this delay in disease, these mice exhibited less astrogliosis and microglial activation in 
the spinal cord (Supplementary Fig. 9d). The time from symptom onset to death (e.g. disease 
duration) was not altered by removal of SOD1 (G37R) from oligodendroglia (−4HT: 180 ± 
17 d; +4HT: 209 ± 15 d, mean ± s.e.m.; n = 12 mice per group, P = 0.246, Mann Whitney 
test), indicating that the prolonged survival of these animals resulted primarily from a delay 
in disease onset. This manipulation decreased SOD1 (G37R) gene level in NG2+ cells by ~ 
43 %, as determined by qPCR from isolated NG2+ cells (data not shown), but preserved its 
expression in motor neurons (Supplementary Fig. 9a). Although this approach had little 
impact on overall tissue levels of SOD1 (G37R) (Supplementary Fig. 9b,c), in keeping with 
the relatively small number of NG2+ cells present (2–5 % of all neural cells in the spinal 
cord)33, it presumably affected all oligodendrocytes generated from SOD1 (G37R) deleted-
NG2+ cells.
Previous studies indicate that oligodendrocytes present at end stage of disease in SOD1 
(G93A) mice express much less MCT19. As oligodendrocytes provide metabolic support to 
axons via this transporter and its expression is downregulated in SOD1 (G93A) mice9, we 
evaluated MCT1 expression in SOD1 (G37R) deleted mice. Removal of SOD1 (G37R) from 
oligodendroglia helped preserve MCT1 expression in some animals at early stages of 
disease (Fig. 8c). Together, these data indicate that expression of mutant SOD1 in NG2+ 
cells and their oligodendrocyte progeny has a deleterious effect on motor neuron survival, 
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and suggest that one negative consequence of mutant SOD1 expression in oligodendrocytes 
is to diminish their capacity to provide metabolic support to neurons.
Discussion
Oligodendrocytes form myelin sheaths around axons in the CNS that enable rapid 
conduction of action potentials at minimal energetic cost. However, the perception that 
oligodendrocytes are primarily structural elements has been challenged by recent evidence 
that they also provide metabolic support to neurons by transferring glycolytic 
intermediates34 through the monocarboxylic transporter MCT19. Motor neurons in the 
spinal cord depend on this transporter for survival, suggesting that oligodendrocyte integrity 
impacts motor neuron fate. Here, we report that there is extensive degeneration of gray 
matter oligodendrocytes in ALS mice that begins prior to the onset of behavioral symptoms 
of disease. Although NG2+ progenitor cells are mobilized to regenerate oligodendrocytes, 
oligodendrocytes generated in later stages of disease exhibit aberrant morphologies and fail 
to restore myelin (see Supplementary Fig. 10). A reduction in gray matter myelin and 
reactive changes in NG2+ cells were frequently observed in the motor cortex and spinal cord 
of ALS patients, indicating that degeneration of gray matter oligodendrocytes is prevalent in 
human ALS. Selective deletion of mutant SOD1 protein from oligodendroglia delayed 
disease onset and prolonged survival in mice, pointing to a key role for these cells in the 
precipitation of disease in ALS. Together, these results suggest that the profound loss of 
gray matter oligodendrocytes in ALS, and the inability to restore oligodendrocyte function, 
accelerates injury to vulnerable motor neurons.
There is accumulating evidence that ALS is not strictly a disease of motor neurons1–3, 35, 36. 
Selective removal of mutant SOD1 (G37R) from motor neurons slowed disease onset, but 
did not alter disease progression, indicating that expression of this mutant gene in other cell 
types is sufficient to cause motor neuron death2. In particular, astrocytes appear to be 
important contributors to disease, as there is a dramatic reduction in astrocyte glutamate 
transporter expression in mouse models of ALS35 and ALS patients37, astrocytes from 
SOD1 (G93A) mice secrete factors that are toxic to motor neurons38, and removal of mutant 
SOD1 from astrocytes delays microglial activation and extends animal survival3. However, 
expression of mutant SOD1 only in astrocytes is not sufficient to induce disease39, 
indicating that astrocyte dysfunction combines with other cellular alterations to accelerate 
the death of motor neurons.
The consequences of mutant protein expression in oligodendrocytes has been examined 
using chimeric mice, in which oligodendrocytes and motor neurons expressed mutant SOD1, 
while all other cells expressed either wild type or mutant SOD140. Remarkably, most of 
these mice survived significantly longer than mice that expressed SOD1 (G37R) 
ubiquitously, and did not exhibit motor neuron degeneration at the time of sacrifice, 
suggesting that alterations in cells other than motor neurons and oligodendrocytes are 
critical for determining disease onset. Nevertheless, our results indicate that selective 
removal of this mutant protein from oligodendrocyte progenitors profoundly slows disease 
progression. It is possible that ALS-linked gene mutations render oligodendrocytes more 
vulnerable to stresses created by abnormalities in other cells, and that oligodendrocyte 
Kang et al. Page 9
Nat Neurosci. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
degeneration is a critical common pathway that forces motor neuron degeneration. Indeed, 
oligodendrocyte vulnerability may be exacerbated by the presence of pro-inflammatory 
cytokines such as interferon-γ41, which at high levels induces apoptosis of 
oligodendrocytes42. Expression of mutant SOD1 in oligodendrocyte progenitors also may 
induce long-term changes in gene expression that increase the vulnerability of 
oligodendrocytes.
Mutations in genes linked to ALS, such as Sod1 (SOD1), Tardbp (TDP-43), and Fus (FUS), 
cause the formation of protein aggregates, often leading to endoplasmic reticulum (ER) 
stress that can induce apoptosis. Ubiquitinated protein aggregates containing TDP-43 have 
been observed in oligodendrocytes in patients with frontotemporal lobar degeneration 
(FTLD)43, and other mutant proteins, such as α-synuclein44 and tau45 accumulate in 
oligodendrocytes in patients with multiple system atrophy (MSA) and other types of 
frontotemporal dementia. These observations raise the possibility that expression of 
aggregation-prone mutant proteins in oligodendrocytes compromises their ability to provide 
adequate support to neurons. Indeed, selective overexpression in oligodendrocytes of a 
mutant form of tau (P301L) associated with human FTD (FTDP-17) led to formation of 
filamentous tau+ inclusions in these cells, eventual oligodendrocyte degeneration and 
reduced myelin31. These animals also exhibited impaired axonal transport, muscle atrophy 
and hind limb weakness, suggestive of motor neuron degeneration. We observed that 
oligodendrocyte degeneration in the spinal cord of ALS mice and demyelination in the 
brains of ALS patients were prominent in gray matter regions near motor neurons, indicating 
that oligodendrocytes in these regions are more susceptible to disease-related stresses. 
Indeed, previous studies have shown that oligodendrocytes in the spinal cord gray matter are 
particularly vulnerable to ER stress when proteolipid protein (PLP), a component of myelin, 
is overexpressed46. Thus, the regional bias in oligodendrocyte vulnerability may depend 
more on metabolic demand, which is related to the type of associated neuron, rather than the 
need for myelination.
Although oligodendrocyte degeneration may be a secondary consequence of motor neuron 
death in ALS, motor axons represent only a minor portion of myelinated fibers in spinal 
cord gray matter. As each oligodendrocyte in the spinal cord forms on average ~ 25 
internodal segments47, each with a different axon, it seems likely that there would be 
sufficient remaining axons to promote oligodendrocyte survival, unless dying motor neurons 
produce pro-apoptotic signals. Furthermore, enhancing oligodendrogenesis without 
appropriate target axons to myelinate would appear maladaptive. Indeed, the increase in 
ultrastructurally normal axons with immature myelin sheaths in ventral gray matter of end 
stage SOD1 (G93A) mice (see Fig. 6a), suggests that oligodendrocytes are attempting to 
remyelinate viable axons, rather than simply degenerating as a result of axon loss. Our 
results also indicate that selective degeneration of motor neurons is not sufficient to enhance 
the proliferation of NG2+ cells in the spinal cord (see Supplementary Fig. 4), which is 
expected to occur if new oligodendrocytes are being formed17, 23, 24. Conversely, 
degeneration of oligodendrocytes and demyelination are sufficient to induce neuronal 
apoptosis, as seen after genetically induced oligodendrocyte ablation25, 26 and in multiple 
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sclerosis (MS)48. Therefore, oligodendrocyte loss is expected to have a profound negative 
impact on the integrity and survival motor neurons during the course of disease.
When do oligodendrocytes begin to degenerate in ALS? Although proliferation of NG2+ 
cells was enhanced well before behavioral onset of disease, their density did not increase, 
due to a concomitant increase in the proportion of cells undergoing differentiation. If this 
increase in oligodendrogenesis compensates for cells lost or injured, as expected from the 
maintenance of oligodendrocyte number (see Fig. 2), then oligodendrocyte degeneration is a 
very early event in the disease process. Despite the continuous regeneration of 
oligodendrocytes, the proportion of incompletely myelinated axons increased, myelin levels 
were reduced, and oligodendrocytes failed to express MCT1, indicating that their maturation 
was impaired. In addition, adult-born oligodendrocytes exhibited morphological 
characteristics of apoptosis, suggesting that their turnover is accelerated. This expanding 
cycle of proliferation, differentiation, and death in the oligodendrocyte lineage in ALS may 
accelerate damage to vulnerable motor neurons by consuming resources and triggering 
reactive changes in other glial cells (see Supplementary Fig. 10).
The degeneration of oligodendrocytes and impaired maturation of oligodendrocyte 
progenitors in ALS shares similarities to progressive forms of MS, where impaired 
remyelination following immune-mediated attack of oligodendrocytes leads to neuronal 
degeneration. Indeed, there is increasing appreciation of gray matter demyelination in MS49. 
Thus, therapeutic approaches that are being developed to treat MS, based on promotion of 
oligodendrocyte survival or enhancement of oligodendroglial metabolic support to neurons, 
also may be helpful for preventing motor neuron degeneration in ALS.
Methods
Animals
PDGFαR-CreER 5 and loxSOD1 (G37R)2 mice were generated and described previously. 
PLP-CreER50 Tg mice were kindly provided by Dr. Brian Popko (U Chicago). SOD1 
(G93A), Z/EG51, ROSA26-EYFP52 and ROSA26-mEGFP (mT/mG)53 mice were purchased 
from the Jackson Laboratory. MOBP-EGFP mice were generated by GENSAT54 and 
purchased from the Mutant Mouse Regional Resource Center (MMRRC). All experiments 
were carried out in strict accordance with protocols approved by the Animal Care and Use 
Committee at Johns Hopkins University.
BrdU labeling and Cre activity induction
For continuous exposure to BrdU (Sigma), mice were provided with BrdU-containing 
drinking water (1 mg/ml supplemented with 1 % sucrose), and received additional BrdU 
injections twice a day (50 mg/kg, i.p., at least 8 hours apart) for 5 consecutive days. 4-
hydroxytamoxifen (4HT, Sigma H7904) was administered, 2 mg (to PLP-CreER;ROSA26-
EYFP) or 4 to 5 mg (to PDGFαR-CreER;Z/EG or PDGFαR-CreER;mTmG) by i.p. injection 
either at P30 or P60. For the excision of SOD1 (G37R), 4HT was injected to PDGFαR-
CreER; loxSOD1 (G37R) mice at P18 (1 mg) and at P30~P31 (total 4 mg). Each mouse 
received up to two injections per day (1 mg per injection), at least 8 hours apart.
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Ricin injection
After anesthesia to P20 mice with Ketamine (120 mg/kg) and Xylazine (8 mg/kg, i.p.), the 
sciatic nerve was exposed and crushed with a fine forcep for 20 seconds, followed by 1 μl of 
1mg/ml ricin (Sigma) injection into the nerve in the proximal side of the crush, and 1 μl of 
PBS in the other side. The animals were sacrificed one week later.
Immunohistochemistry
Mice were deeply anesthetized with sodium pentobarbital (100 mg/kg b.w.) and perfused 
transcardially with 4 % paraformaldehyde (PFA in 0.1M phosphate buffer, pH 7.4). Spinal 
cords were further post-fixed overnight at 4 °C. For immunofluorescence, lumbar spinal 
cords were stored at 4 °C for more than 36 hours in 30 % sucrose solution (in PBS, pH 7.4), 
and then sectioned with a cryostat (35 μm or 25μm thick). Immunofluorescence was 
performed on free-floating sections as described previously5. We used primary antibodies to 
APC (CC1) (mouse, Calbiochem, 1:50), BrdU (rat, Accurate, 1:500), Caspase-3 (rabbit, Cell 
Signaling, 1:500), ChAT (goat, Millipore, 1:300), EGFP (goat, Frontier Institute, 1:500), 
EGFP (rabbit, a gift from Dr. Richard Huganir, Johns Hopkins University, 1:500), GFAP 
(mouse, NeuroMab, 1:500), GFAP (rabbit, DAKO, 1:1,000), Iba1 (rabbit, Wako, 1:1,000), 
Ki67 (rabbit, Abcam, 1:500), NG2 (guinea pig, 1:3,600), Olig2 (guinea pig, a gift from Dr. 
Ben Novitch, UCLA, 1:20,000), Olig2 (rabbit, Millipore, 1:500), PDGFαR (rabbit, a gift 
from Dr. William Stallcup, Burnham Institute, 1:500), SMI32 (mouse, Covance, 1:1,000), 
and hSOD1 (rabbit, 1:70). Secondary antibodies were Alexar Fluor 488-(Invitrogen 1:500), 
or Cy3-, DyLight 549-, Cy5-, or DyLight 649- conjugated donkey F(ab′)2 fragments against 
rabbit, goat, mouse, rat, or guinea pig (Jackson ImmunoResearch). For Olig2, ALDH or 
APC (CC1) immunostaining, tissue sections were incubated in LAB solution (Polysciences) 
for 10 minutes before blocking. For BrdU staining, sections were preincubated in 2N HCl at 
37 °C for 30 minutes, followed by neutralization with 0.1 M sodium borate buffer (pH 8.5) 
prior to immunolabeling. DAPI was added during the secondary antibody incubation for 
most cases. Sections were mounted on slides with ProLong antifade reagent (Invitrogen).
For human tissue histopathological analysis, paraffin-embedded and fresh frozen human 
primary motor cortex and lumbar spinal cord sections (all 5 μm thick) were used. Sections 
were deparaffinized in a series of xylene, 100 % alcohol, 95 % alcohol, 70 % alcohol and 
water, followed by antigen retrieval (boiling in 10 mM Citrate buffer at pH 6.0 for 10 min). 
Sections were incubated with 3 % H2O2, blocked with 3% BSA in PBS, and incubated with 
the primary antibody for 60 minutes at room temperature or at 4° C overnight. We used 
primary antibodies to Iba1 (rabbit, Wako, 1:1,000), MBP (rabbit, Millipore, 1:200), and 
NG2 (mouse, BD Science, 1:1,000). Sections were incubated with biotinylated secondary 
antibodies (Vector Lab), followed by VECTASTAIN Elite ABC reagent according to the 
manufacture’s instruction (Vector Lab) and colorimetrically developed using the 3,3′-
diaminobenzidine (DAB) substrate kit (Vector Lab). For double labeling of NG2 and Iba1, 
mounted fresh frozen sections (5μm) were fixed with 4 % PFA at room temperature for 15 
minutes, incubated with 3 % H2O2, blocked with 3 % BSA, and then incubated with anti-
NG2 antibody at 4° C overnight. Sections were incubated with HRP labeled secondary 
antibody and Renaissance TSA Biotin system (PerkinElmer) according to manufacturer’s 
instructions, and developed with DAB substrate. For Iba1 staining, sections was blocked 
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with the BLOXALL solution (Vector Lab), followed by alkaline phosphatase conjugated 
secondary antibody (Promega) and developed with NBT/BCIP substrate (Vector Lab).
Luxol fast blue myelin staining
Tissue sections were stained with 0.1 % luxol fast blue solution (Sigma) at 60° C overnight. 
Sections were rinse with 95 % ethanol and water, reacted with 1 % lithium carbonate 
solution and 70 % ethanol, followed by rinsing in water. Counter staining with hematoxylin 
and eiosin was performed, as necessary.
Microscopy and cell counting
Mounted slides were imaged using an epifluorescence microscope (Zeiss Axio-imager M1), 
and Axiovision software (Zeiss), or a confocal laser scanning microscope (Zeiss LSM 510 
Meta) using appropriate excitation and emission filters. A total of 3 – 5 sections were 
examined per mouse, and 3 – 4 mice were analyzed per each data point. Confocal images 
represent projected stacks of 15 – 45 images collected at 0.5 – 1.5μm steps.
Volume measurement of oligodendrocyte cellular fragments
EGFP+ elements of MOBP-EGFP mice that are not associated with Olig2 were quantified 
using a commercially available 3D analysis package (Imaris; Bitplane). EGFP+ structures 
were defined by applying an absolute intensity threshold, followed by thresholding for 
structure size to remove small objects. Identical thresholds were applied to all images. 
EGFP+ structures that were also associated with Olig2 staining were deleted, as were 
structures which were positioned at the edge of the imaged field. The volume of Olig2− 
EGFP+ was scaled according to total imaged volume.
Electron microscopy
Mice were perfused transcardially with 4 % paraformaldehyde/2.5 % glutaraldehyde in 0.1 
M Phosphate buffer (PB) under deep anesthesia, and brain tissue was isolated and post-fixed 
for 4 hours at 4 °C. Brains were treated with 2 % OsO4 for 1 hour, and washed in water. 
Samples were incubated in 2 % uranyl acetate for 30 minutes and dehydrated using 50 %, 70 
%, 90 %, 100 % ethanol, and propylene oxide. Samples were embedded in Epon 812 resin 
(Ted Pella). Ultrathin sections were obtained using Ultracut UCT (Leica) and stained with 2 
% uranyl acetate and lead citrate. Electron micrographs were taken with an H-7600 electron 
microscope (Hitachi, Tokyo, Japan). Image J was used to measure the diameter of axons and 
myelin sheath.
For pre-embedding immunoelectron microscopy, 4HT-injected PDGFαR-CreER;ROSA26-
mEGFP ± SOD1 (G93A) mice (P60+60) were perfused transcardially with 4 % 
paraformaldehyde/0.1 % glutaraldehyde in 0.1 M PB under deep anesthesia. After blocking 
with 5% normal donkey serum in PBS, spinal cord sections (50 μm thick) were incubated 
overnight with rabbit anti-EGFP IgG and then with anti-rabbit IgG conjugated to 1.4 nm 
gold particles (Nanoprobes). Following silver enhancement (HQ silver, Nanoprobes), 
sections were osmificated, dehydrated and embedded in Epon 812 resin. Ultrathin sections 
were prepared with an ultramicrotome (Leica) and stained with 2 % uranyl acetate.
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Clinical materials
Human autopsy materials including frozen and paraffin-embedded control and ALS patient 
cortex and spinal cord tissues were obtained from the Johns Hopkins University ALS Clinic, 
Brain Resource Center/Department of Pathology, VA Biorepository Brain Bank. All 
experiments were performed using motor cortex, cervical and/or lumbar spinal cord tissues. 
All available demographic information for the ALS and control cases analyzed in this study 
is presented in the Supplementary Table 1.
Western blotting
Lumbar spinal cords were collected from control and SOD1 (G93A) mice, snap frozen in 
liquid nitrogen, and then stored at −80° C until use. For human cortex protein analysis, the 
gray matter and white matter were separated grossly. The tissues were homogenized in 
RIPA buffer (Thermo) supplemented with proteinase inhibitor (Roche) and phosphatase 
inhibitor (Calbiochem) on dry ice. Thirty microgram of protein was separated on 4 – 12 % 
gradient Bis-Tris gels (BioRad) or NuPage and transferred to nitrocellulose membranes 
(BioRad). After blocking with 5 % nonfat milk, membranes were probed with primary 
antibodies at 4° C overnight, following by HRP conjugated secondary antibodies, 
Supersignal Pico detection reagent (Pierce), and then exposed to HyBlot CL 
autoradiography film (Denville). The intensity for each band was quantified with Image J 
software. The antibodies used for western are antibodies to CNPase (mouse, Millipore, 
1:1,000), MBP (mouse, Millipore, 1:2,000), PDGFαR (rabbit, Santa Cruz, 1:200), GAPDH 
(rabbit, Cell Signaling, 1:1,000) and MCT1 (rabbit, Santa Cruz, 1:100).
Analysis of disease progression
For PDGFαR-CreER;loxSOD1 (G37R) mice, the time of disease onset, early disease and 
end stage were defined as the time when mouse body weight reached the peak, body weight 
declined to 10 % of the maximum weight, and paralyzed animals could not right itself 
within 20 seconds when placed on its side respectively, as previously described2. The total 
disease duration was defined as the duration between disease onset and end stage. Animals 
were weighted once a week when they were 150 days old.
qPCR determination of transgene excision in NG2+ cells
The brain neural cells from two-month old animals (with and without 4HT injection, n = 3 
each group) were dissociated using Dissociation Kit (P) (Milteny) by following the 
manufacturer’s instructions. Myelin was removed by using Percoll generated gradient. Live 
cell fraction was collected and the cells were submitted to staining for PDGFαR (1:200, 
Santa Cruz) and followed by Alexa anti-rabbit 488 before Fluorescence-activated cell 
sorting (FACS) analysis. Dead cells were excluded by propidium iodide (PI) staining during 
sorting using MoFlo MLS high-speed cell sorter (Beckman Coulter) at Johns Hopkins 
School of Public Health FACS core. Only PDGFαR+ and PI- cells were sorted out for 
transgene evaluation. Genomic DNA was extracted by using QIAmp DNA micro kit 
(Qiagen) following the manufacturer’s instructions. qPCR for SOD1 (G37R) transgene was 
performed using the primers and cycler parameters on ABI Plusone cycler as described 
previously2.
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Statistical analysis
All data are presented as mean ± standard error of the mean (s.e.m.). For multiple groups, 
data were evaluated by one-way ANOVA and further evaluated with Tukey post hoc 
comparisons. Otherwise, unpaired Student’s t-test was applied. P < 0.05 was considered to 
be statistically significant. The paired Student’s t-test was used to evaluate contralateral and 
ipsilateral side of cell counts in ricin injected animal study. Log-Rank test was used for 
survival curve analysis. Mann Whitney test was used for disease duration.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Naiqing Ye, Isha Srivastava, Sujal Singh and Truong Le for their excellent technical support, Dr. Michele 
Pucak for help with Imaris software operation and quantitative analysis, Dr. Jessica Carmen for her contributions to 
the Cre/lox animal study, and Hao Zhang at the Johns Hopkins University School of Public Health FACS core for 
assistance with NG2+ cell isolation. We thank Dr. Bruce Trapp (Cleveland Clinic Lerner Research Institute) for 
advice regarding human NG2+ cell staining, Dr. Ranjan Dutta (Cleveland Clinic Lerner Research Institute) for 
advice regarding protein extraction from human tissues, and Dr. Brian Popko (University of Chicago) for providing 
PLP-CreER mice. Human samples were provided by Dr. Robert Bowser at Barrow Neurological Institute, Dr. 
Katrina Trevor at SACTL-VA Biorepository Trust and SACTL-VA Biorepository Trust, Dr. Thomas Hyde at the 
Lieber Institute for Brain Development, and the Johns Hopkins School of Medicine Dept. of Neuropathology. We 
thank Elizabeth Mosmiller for helping with patient demographic information. We also thank Drs. Amit Agarwal 
and Abraham Langseth for critical discussions. This work was supported by grants from P2ALS (to D.E.B. and 
J.D.R.), the NIH (NS27036 to D.W.C, NS33958 to J.D.R and NS051509 to D.E.B), the ALS Association 
(4ZMUDE to Y.L.), the Robert Packard Center for ALS Research at Johns Hopkins, and the Brain Science 
Institute.
References
1. Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in 
ALS mice. Science. 2003; 302:113–117. [PubMed: 14526083] 
2. Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and 
microglia. Science. 2006; 312:1389–1392. [PubMed: 16741123] 
3. Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic 
lateral sclerosis. Nat Neurosci. 2008; 11:251–253. [PubMed: 18246065] 
4. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative 
disorders: ALS and beyond. J Cell Biol. 2009; 187:761–772. [PubMed: 19951898] 
5. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2+ CNS glial progenitors remain 
committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. 
Neuron. 2010; 68:668–681. [PubMed: 21092857] 
6. Magnus T, et al. Adult glial precursor proliferation in mutant SOD1G93A mice. Glia. 2008; 56:200–
208. [PubMed: 18023016] 
7. Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010; 468:244–252. 
[PubMed: 21068833] 
8. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev 
Neurosci. 2008; 31:535–561. [PubMed: 18558866] 
9. Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. 
Nature. 2012; 487:443–448. [PubMed: 22801498] 
10. Suzuki A, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. 
Cell. 2011; 144:810–823. [PubMed: 21376239] 
11. Rinholm JE, et al. Regulation of oligodendrocyte development and myelination by glucose and 
lactate. J Neurosci. 2011; 31:538–548. [PubMed: 21228163] 
Kang et al. Page 15
Nat Neurosci. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
12. Niebroj-Dobosz I, Rafalowska J, Fidzianska A, Gadamski R, Grieb P. Myelin composition of 
spinal cord in a model of amyotrophic lateral sclerosis (ALS) in SOD1G93A transgenic rats. Folia 
Neuropathol. 2007; 45:236–241. [PubMed: 18176898] 
13. Cosottini M, et al. Magnetization transfer imaging demonstrates a distributed pattern of 
microstructural changes of the cerebral cortex in amyotrophic lateral sclerosis. AJNR Am J 
Neuroradiol. 2011; 32:704–708. [PubMed: 21436337] 
14. Rivers LE, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform 
projection neurons in adult mice. Nat Neurosci. 2008; 11:1392–1401. [PubMed: 18849983] 
15. Zhu X, et al. Age-dependent fate and lineage restriction of single NG2 cells. Development. 2011; 
138:745–753. [PubMed: 21266410] 
16. Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide 
dismutase mutation. Science. 1994; 264:1772–1775. [PubMed: 8209258] 
17. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene 
for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of 
familial amyotrophic lateral sclerosis (FALS). Brain Res. 1995; 676:25–40. [PubMed: 7796176] 
18. Woodruff RH, Tekki-Kessaris N, Stiles CD, Rowitch DH, Richardson WD. Oligodendrocyte 
development in the spinal cord and telencephalon: common themes and new perspectives. Int J 
Dev Neurosci. 2001; 19:379–385. [PubMed: 11378298] 
19. Guo F, et al. Pyramidal neurons are generated from oligodendroglial progenitor cells in adult 
piriform cortex. J Neurosci. 2010; 30:12036–12049. [PubMed: 20826667] 
20. Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat 
Neurosci. 2005; 8:752–758. [PubMed: 15895084] 
21. Jamin N, Junier MP, Grannec G, Cadusseau J. Two temporal stages of oligodendroglial response to 
excitotoxic lesion in the gray matter of the adult rat brain. Exp Neurol. 2001; 172:17–28. 
[PubMed: 11681837] 
22. Wu YJ, Tang YF, Xiao ZC, Bao ZM, He BP. NG2 cells response to axonal alteration in the spinal 
cord white matter in mice with genetic disruption of neurofilament light subunit expression. Mol 
Neurodegener. 2008; 3:18. [PubMed: 18957081] 
23. Coutts M, Kong LX, Keirstead HS. A model of motor neuron loss: selective deficits after ricin 
injection. J Neurotrauma. 2010; 27:1333–1342. [PubMed: 20486802] 
24. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol. 2001; 11:R795–805. 
[PubMed: 11591341] 
25.  , . , . 
26. Locatelli G, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci. 
2012; 15:543–550. [PubMed: 22366759] 
27. Pohl HB, et al. Genetically induced adult oligodendrocyte cell death is associated with poor myelin 
clearance, reduced remyelination, and axonal damage. J Neurosci. 2011; 31:1069–1080. [PubMed: 
21248132] 
28. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ. Platelet-derived growth factor regulates 
oligodendrocyte progenitor numbers in adult CNS and their response following CNS 
demyelination. Mol Cell Neurosci. 2004; 25:252–262. [PubMed: 15019942] 
29. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor 
cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000; 20:6404–6412. 
[PubMed: 10964946] 
30. Pouly S, Becher B, Blain M, Antel JP. Expression of a homologue of rat NG2 on human microglia. 
Glia. 1999; 27:259–268. [PubMed: 10457372] 
31. Bu J, Akhtar N, Nishiyama A. Transient expression of the NG2 proteoglycan by a subpopulation of 
activated macrophages in an excitotoxic hippocampal lesion. Glia. 2001; 34:296–310. [PubMed: 
11360302] 
32. Higuchi M, et al. Axonal degeneration induced by targeted expression of mutant human tau in 
oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci. 2005; 25:9434–9443. 
[PubMed: 16221853] 
Kang et al. Page 16
Nat Neurosci. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
33. Yazawa I, et al. Mouse model of multiple system atrophy alpha-synuclein expression in 
oligodendrocytes causes glial and neuronal degeneration. Neuron. 2005; 45:847–859. [PubMed: 
15797547] 
34. Horner PJ, Thallmair M, Gage FH. Defining the NG2-expressing cell of the adult CNS. J 
Neurocytol. 2002; 31:469–480. [PubMed: 14501217] 
35. Funfschilling U, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. 
Nature. 2012; 485:517–521. [PubMed: 22622581] 
36. Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes 
rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997; 18:327–338. 
[PubMed: 9052802] 
37. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of 
mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 
2001; 21:3369–3374. [PubMed: 11331366] 
38. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate 
transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995; 38:73–84. [PubMed: 
7611729] 
39. Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic 
to motor neurons. Nat Neurosci. 2007; 10:615–622. [PubMed: 17435755] 
40. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL. Restricted expression of G86R 
Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron 
degeneration. J Neurosci. 2000; 20:660–665. [PubMed: 10632595] 
41. Yamanaka K, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes 
accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A. 2008; 105:7594–7599. 
[PubMed: 18492803] 
42. Aebischer J, et al. Elevated levels of IFNgamma and LIGHT in the spinal cord of patients with 
sporadic amyotrophic lateral sclerosis. Eur J Neurol. 2012; 19:752–759. [PubMed: 22221541] 
43. Buntinx M, et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic 
effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res. 2004; 76:834–845. [PubMed: 
15160395] 
44. Neumann M, et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration 
with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007; 66:177–183. [PubMed: 
17356379] 
45. Tu PH, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system 
atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998; 44:415–422. [PubMed: 
9749615] 
46. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal 
degeneration and Pick’s disease. Brain Pathol. 1999; 9:663–679. [PubMed: 10517506] 
47. Bauer J, et al. Endoplasmic reticulum stress in PLP-overexpressing transgenic rats: gray matter 
oligodendrocytes are more vulnerable than white matter oligodendrocytes. J Neuropathol Exp 
Neurol. 2002; 61:12–22. [PubMed: 11829340] 
48. Chong SY, et al. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of 
oligodendrocyte myelination. Proc Natl Acad Sci U S A. 2012; 109:1299–1304. [PubMed: 
22160722] 
49. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 
2007; 68:S22–31. discussion S43–54. [PubMed: 17548565] 
50. Rudick RA, Trapp BD. Gray-matter injury in multiple sclerosis. N Engl J Med. 2009; 361:1505–
1506. [PubMed: 19812410] 
51. Doerflinger NH, Macklin WB, Popko B. Inducible site-specific recombination in myelinating cells. 
Genesis. 2003; 35:63–72. [PubMed: 12481300] 
52. Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double reporter mouse line that expresses 
enhanced green fluorescent protein upon Cre-mediated excision. Genesis. 2000; 28:147–155. 
[PubMed: 11105057] 
53. Srinivas S, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the 
ROSA26 locus. BMC Dev Biol. 2001; 1:4. [PubMed: 11299042] 
Kang et al. Page 17
Nat Neurosci. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
54. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter 
mouse. Genesis. 2007; 45:593–605. [PubMed: 17868096] 
55. Gong S, et al. A gene expression atlas of the central nervous system based on bacterial artificial 
chromosomes. Nature. 2003; 425:917–925. [PubMed: 14586460] 
Kang et al. Page 18
Nat Neurosci. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Enhanced proliferation of NG2+ cells in the spinal cord of pre-symptomatic ALS mice. (a) 
BrdU protocol used to assess proliferation of NG2+ cells in control and SOD1 (G93A) mice. 
(b) Fluorescence images showing BrdU+ cells in the ventral horn of the spinal cord in 
control and SOD1 (G93A) mice at P60. Panels at right show two BrdU+ NG2+ cells in the 
ventral gray matter. Scale bar: 100 μm. (c – e) Graphs showing the density of proliferating 
oligodendrocyte lineage cells (BrdU+Olig2+) in different regions of spinal cord at different 
ages in control (white bars) and SOD1 (G93A) (gray bars) mice. (f – h) Graphs showing the 
density of NG2+ cells (PDGFαR+) in different regions of the spinal cord at different stages 
of disease (P75 (pre-symptomatic), P90 (symptomatic), and P120 (end stage)), as compared 
to wild type mice. GM, gray matter; WM, white matter. Mean + s.e.m. (n = 9 sections 
obtained from 3 mice per group), *P < 0.05, ** P < 0.001, *** P < 0.0005, unpaired 
Student’s t-test.
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Figure 2. 
Enhanced oligodendrogenesis in the spinal cord gray matter of adult ALS mice. (a) Protocol 
used to trace the fate of NG2+ cells in PDGFαR-CreER;Z/EG ± SOD1 (G93A) mice. 
Cohorts of NG2+ cells were labeled with EGFP by 4HT injection at P30 or P60 then 
analyzed at different ages. (b) Fluorescence images showing EGFP+ NG2+ cell progeny in 
the ventral horn of the spinal cord in control or SOD1 (G93A) mice 60 days after 4HT 
administration at P30 (P30+60). Scale bar: 100 μm. (c – e) Maps of the location of adult 
born oligodendrocytes generated from NG2+ cells in the spinal cord of control (blue circles) 
or SOD1 (G93A) mice (red circles), from P60 to P75 (c), from P60 to P90 (d), or from P60 
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to P120 (or end stage for ALS mice) (e). Oligodendrocytes (EGFP+CC1+) in four randomly 
sampled lumbar spinal cord sections from each group (from 3–4 mice) are shown. (f – h) 
Graphs showing the density of newly generated EGFP+ CC1+ oligodendrocytes in different 
regions of the adult spinal cord from control (white bars) and SOD1 (G93A) mice (gray 
bars). Mean + s.e.m. (n = 9 sections from 3 mice per group) * P < 0.05, ** P < 0.001, *** P 
< 0.0005, unpaired Student’s t test. i) Graph showing the overall density of oligodendrocytes 
(Olig2+CC1+) in different regions of the spinal cord of P120 and end stage SOD1 (G93A) 
mice. Mean + s.e.m. (n = 12 sections per group from 4 mice per group) N.S., non-
significant, one-way ANOVA with Tukey test.
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Figure 3. 
Progressive degeneration of oligodendrocytes in the spinal cord ventral gray matter of ALS 
mice. (a) Protocol used to track the fate of early-born oligodendrocytes. Littermate control 
and SOD1 (G93A) expressing PLP-CreER;ROSA26-EYFP mice received 4HT (2 mg) at 
P35 and were analyzed at P40, P50, P90 and P120 (or end stage for ALS mice). (b) 
Schematic showing the rationale and possible outcomes of oligodendrocyte fate analysis. 
(c,d) Plot of the number of EYFP+ oligodendrocytes (CC1+Olig2+) in ventral gray mater 
(GM) (c) and ventral white matter (WM) (d) of PLP-CreER;ROSA26-EYFP ± SOD1 
(G93A) mice, expressed relative to the number observed at P35+15 (P50). Note that control 
group had additional time point (P35+10). Means ± s.e.m. (n = 9 sections from 3 mice per 
each time point of each group). * P < 0.05, ** P < 0.001, *** P < 0.0005. Unpaired 
Student’s t-test was used to compare mean values between control and SOD1 (G93A) mice 
at each time point. One-way ANOVA with Tukey test was used for age-dependent relative 
changes in EYFP+ oligodendrocytes in each group. (e) Confocal images showing the density 
and morphology of EYFP+ (stained with anti-EGFP antibody) CC1+Olig2+ spinal cord 
oligodendrocytes (yellow arrows) in ventral gray matter at P120 (control) or at end stage 
SOD1 (G93A) mice. Scale bars: 20μm.
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Figure 4. 
Apoptosis of oligodendrocytes in the spinal cord of ALS mice. (a) Confocal images from the 
spinal cord ventral gray matter of a MOBP-EGFP;SOD1 (G93A) mouse at end stage 
showing an EGFP+ oligodendrocyte (yellow arrow) that was immunopositive for activated 
caspase-3. Lower right panel is an orthogonal view showing co-localization of activated 
caspase-3 and EGFP. (b,c) Confocal images of the spinal cord ventral gray matter showing 
Iba1+ activated microglia surrounding oligodendrocytes labeled with EGFP (b) or EYFP (c) 
in SOD1 (G93A) expressing MOBP-EGFP (P90) or PLP-CreER;ROSA26-EYFP (P30+60) 
mice, respectively. Yellow arrowheads highlight several labeled oligodendrocytes, and 
white arrows in (c) highlight the processes of one EYFP+ oligodendrocyte. Scale bars: 20 
μm.
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Figure 5. 
Early disruption of oligodendrocyte structure in the spinal cord of ALS mice. (a,b) Confocal 
images of EGFP+ structures in the ventral spinal cord gray matter from control MOBP-
EGFP (P120) and MOBP-EGFP;SOD1 (G93A) mice (end stage). Panels in (b) show regions 
highlighted by white squares in (a). Arrowheads indicate large EGFP+ structures that were 
Olig2− and CC1−. Scale bars: 20 μm. (c) Measured volume of Olig2− EGFP+ fragments in 
each 250,000 μm3 imaged volume. Mean + s.e.m. (n = 6 – 9 sections from 3 mice per group) 
** P = 1.5 × 10−5, *** P = 8 × 10−6, unpaired Student’s t-test.
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Figure 6. 
Myelin abnormalities and impaired maturation of adult-born oligodendrocytes in the spinal 
cord of ALS mice. (a) Electron micrographs of ventral gray matter spinal cord of control 
(P120) and SOD1 (G93A) mice at end stage. Arrows highlight partially myelinated axons. 
Note the presence of thick oligodendrocyte cytoplasm surrounding these axons. (b) 
Confocal images of MBP immunoreactivity in ventral gray matter of P120 MOBP-EGFP 
mice or end stage MOBP-EGFP;SOD1 (G93A) mice. Optical sections: 1.5 μm. (c) 
Fluorescent images of membrane-anchored EGFP in the spinal cord of PDGFαR-
CreER;ROSA26-mEGFP mice (P60+60). (d) Confocal images showing fine EGFP+ 
processes of adult-born oligodendrocytes in ventral gray matter of PDGFαR-
CreER;ROSA26-mEGFP ± SOD1 (G93A) mice (P60+60). Circles indicate ChAT+ motor 
neuron cell bodies and white arrows indicate NG2− oligodendrocyte processes. (e) Confocal 
images showing co-localization of EGFP+ thin processes and MBP immunoreactivity (white 
arrows) in control PDGFαR-CreER; ROSA26-mEGFP mice (P60+60) (upper images). MBP 
immunoreactivity was more disorganized in PDGFαR-CreER; ROSA26-mEGFP 
mice;SOD1 (G93A) mice (lower panel) and rarely co-localized with EGFP+ processes 
(P60+60) (yellow arrowhead). Optical sections: 0.5 μm. (f–h) Thin section electron 
micrographs from PDGFαR-CreER;ROSA26-mEGFP ± SOD1 (G93A) mice at P60+60 
showing silver-intensified gold labeling of EGFP+ oligodendrocyte processes. Large, non-
myelinating EGFP+ structures (arrowheads) reminiscent of apoptotic bodies were observed 
frequently in SOD1 (G93A) mice (h). Scale bars: 1μm (a), 20 μm (b, d, e), 200 μm (c), 500 
nm (f–h).
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Figure 7. 
Demyelination in gray matter regions of the motor cortex and spinal cord in human ALS. (a) 
Sections of motor cortex gray matter from control and ALS patients showing 
immunoreactivity to NG2. NG2+ cells are highlighted by arrowheads. See NG2/Iba1 co-
immunostained images in Supplementary Fig. 8a. Images were acquired from cortical layers 
IV and V. Scale bars: 20 μm. (b) Luxol fast blue staining of motor cortices from control 
subjects and ALS patients. Demyelinated lesions are highlighted by arrowheads (upper right 
panel) or a dashed line (lower panel). (c) MBP immunoreactivity in ALS motor cortex. 
Adjacent sections to those shown in the upper right and lower panels in (b) were used. 
Images show demyelinated plaques in layer III (upper panel) and layer V (lower panel). (d) 
Sections of lumbar spinal cord from an ALS patient stained with Luxol fast blue showing 
demyelination in the ventral horn gray matter and lateral corticospinal tract (arrowhead). 
Lower panels are higher magnification images of the boxed regions in the upper panels. 
Scale bars: 1 mm (b,d upper panels); 200 μm (c,d lower panels). (e, g) Western blots of 
oligodendrocyte lineage-specific myelin proteins in motor cortex gray matter (e) and lumbar 
spinal cord ventral horn grey matter (g) from controls and ALS patients. Full-length blots 
are presented in Supplementary Fig. 11. (f, h) Graphs of MBP and CNPase protein 
expression levels (measured by Western blot) in the motor cortex (f) and lumbar spinal cord 
ventral horn (h) gray matter in controls and ALS patients, normalized to average value in 
controls. Mean ± s.e.m. with individual values. * P < 0.05, *** P < 0.0001, unpaired 
Student’s t-test.
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Figure 8. 
Excision of mutant SOD1 (G37R) from NG2+ cells delays disease onset and prolongs 
survival in ALS mice. (a) Plots of disease onset (median, −4HT: 235 d (n = 15); +4HT: 304 
d (n = 20), P = 0.0003, Log-Rank test), early disease (median, −4HT: 330 d (n = 13); +4HT: 
413 d (n = 14), P = 0.001), and survival (median, −4HT: 419 d (n = 12); +4HT: 554 d (n = 
14), P = 0.0005) of PDGFαR-CreER;loxSOD1 (G37R) mice. (b) Comparison of mean age 
at disease onset (−4HT: 244 ± 10 d; +4HT: 307 ± 11 d, P = 0.0005), early disease (−4HT: 
336 ± 16 d; +4HT: 415 ± 13 d, P = 0.001) and survival (−4HT: 433 ± 18 d; +4HT: 518 ± 16 
d, P = 0.0025,). Mean + s.e.m. ** P < 0.01; *** P < 0.005, Mann Whitney test. (c) Western 
blots of MCT1 expression from several −4HT and +4HT mice examined at disease onset. 
Full-length blots are presented in Supplementary Fig. 11.
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